Newlink Genetic Corp. shares fell in the extended session Monday after the biotech said it will continue a pancreatic cancer drug clinical trial without any modification to the study plan. Newlink shares fell 17% to $43.16 on moderate volume. Newlink said an independent data safety monitoring committee recommended the company proceed with a statistical analysis plan agreed to by the Food and Drug Administration for the study.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below